<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006642</article-id><article-id pub-id-type="pmc">PMC11859819</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020275</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00275</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics of Levofloxacin Entrapped in Non-Ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3467-2433</contrib-id><name><surname>Adebayo</surname><given-names>Amusa S.</given-names></name><xref rid="af1-pharmaceutics-17-00275" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00275" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3871-5146</contrib-id><name><surname>Jankie</surname><given-names>Satish</given-names></name><xref rid="af2-pharmaceutics-17-00275" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Jenelle</given-names></name><xref rid="af3-pharmaceutics-17-00275" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4350-4319</contrib-id><name><surname>Pereira</surname><given-names>Lexley Pinto</given-names></name><xref rid="af4-pharmaceutics-17-00275" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Agbaje</surname><given-names>Kafilat</given-names></name><xref rid="af1-pharmaceutics-17-00275" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Adesina</surname><given-names>Simeon K.</given-names></name><xref rid="af1-pharmaceutics-17-00275" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Batty</surname><given-names>Kevin T.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Davies</surname><given-names>Neal M.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00275"><label>1</label>Department of Pharmaceutical Sciences, College of Pharmacy, Howard University, 2300 4th Street NW, Rm 309, Washington, DC 20059, USA; <email>kafilat.agbaje@bison.howard.edu</email> (K.A.); <email>simeon.adesina@howard.edu</email> (S.K.A.)</aff><aff id="af2-pharmaceutics-17-00275"><label>2</label>School of Pharmacy, Faculty of Medical Sciences, University of the West Indies, St. Augustine, Trinidad and Tobago; <email>satish.jankie@sta.uwi.edu</email></aff><aff id="af3-pharmaceutics-17-00275"><label>3</label>School of Veterinary Medicine, Faculty of Medical Sciences, University of the West Indies, St. Augustine, Trinidad and Tobago; <email>jenelle.johnson2@sta.uwi.edu</email></aff><aff id="af4-pharmaceutics-17-00275"><label>4</label>Department of Paraclinical Sciences, Faculty of Medical Sciences, University of the West Indies, St. Augustine, Trinidad and Tobago; <email>lexley.pintopereira@sta.uwi.edu</email></aff><author-notes><corresp id="c1-pharmaceutics-17-00275"><label>*</label>Correspondence: <email>amusa.adebayo@howard.edu</email>; Tel.: +1-202-806-4493</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>275</elocation-id><history><date date-type="received"><day>26</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives</bold>: Bacteria are becoming increasingly resistant to levofloxacin and other fluoroquinolones. Previously, drug loading in colloidal carriers has shown enhanced penetration into and retention in bacterial cells. However, the mechanism of levofloxacin niosomes&#x02019; bio-disposition in rats has not been reported. This study investigated the pharmacokinetics (PK) of optimized levofloxacin niosomes following intraperitoneal injection into Sprague Dawley rats. <bold>Methods</bold>: Formulation and processing variables settings were determined using DoE Fusion One software. The resulting data input into the Optimizer module provided niosome formulation for in vivo study in Sprague Dawley rats. Each group of rats (n = 6) was injected intraperitoneally with either conventional levofloxacin or its niosomes at equivalent doses of 7.5 mg/kg/dose. Blood samples were collected via tail snip and analyzed using a validated HPLC method. The plasma&#x02013;time data were fed into the Gastroplus software (Simulations Plus, CA) and used to model levofloxacin PK. <bold>Results</bold>: Niosomes for in vivo study had a mean hydrodynamic diameter of 329.16 nm (&#x000b1;18.0), encapsulation efficiency (EE) of 30.74%, Zeta potential of 21.72 (&#x000b1;0.54), and polydispersity index (PDI) of 0.286 (&#x000b1;0.014). Both the Akaike and Schwarz criteria showed levofloxacin niosomes and conventional drug formulation obeying one- and two-compartment PK models, respectively. Thus, formulation in niosomes altered levofloxacin biodistribution by concentrating the drug in the vascular compartment. <bold>Conclusions</bold>: Niosome encapsulation of levofloxacin altered its biodistribution and pharmacokinetic profile, possibly by protecting i.p. levofloxacin en route into plasma, and significantly enhanced its plasma concentration with enhanced potential for treating intravascular infections.</p></abstract><kwd-group><kwd>niosomes</kwd><kwd>levofloxacin</kwd><kwd>pharmacokinetics</kwd><kwd>Sprawgue Dawley rats</kwd></kwd-group><funding-group><award-group><funding-source>Georgetown Howard Universities Center for Clinical and Translational Science (GHUCCTS)-Pilot Translational and Clinical Studies</funding-source><award-id>GRT000558</award-id></award-group><funding-statement>This research was funded by the Georgetown Howard Universities Center for Clinical and Translational Science (GHUCCTS)-Pilot Translational and Clinical Studies, Grant #: GRT000558.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00275"><title>1. Introduction</title><p>Niosomes are non-ionic surfactant vesicles usually stabilized with cholesterol and charge-inducing agents. The microscopic lamellar structure formed from the admixture of non-ionic surfactant and cholesterol has the ability to accommodate drugs of various molecular nature with a wide range of solubilities. Niosomes are similar to liposomes in chemical structure and physical properties [<xref rid="B1-pharmaceutics-17-00275" ref-type="bibr">1</xref>]. Unlike liposomes, niosomes are osmotically active and stable in physiologic fluids and have greater potential for increasing the stability of entrapped drugs. The surfactants used for niosome construction are biodegradable, biocompatible, and non-immunogenic, and the formulation requires no special handling or storage conditions [<xref rid="B2-pharmaceutics-17-00275" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00275" ref-type="bibr">3</xref>]. Therefore, niosomes are growing in therapeutic applications for the delivery of a wide range of drugs for various conditions [<xref rid="B1-pharmaceutics-17-00275" ref-type="bibr">1</xref>,<xref rid="B4-pharmaceutics-17-00275" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00275" ref-type="bibr">5</xref>].</p><p>Studies have shown that the distribution and localization of colloidal carriers in tissues and cellular and sub-cellular areas parallel the distribution into the common bacteria cells that are responsible for intracellular infections [<xref rid="B6-pharmaceutics-17-00275" ref-type="bibr">6</xref>]. Topoisomerases, the target enzymes for fluoroquinolones, are in the bacteria cytoplasm, and changes in the permeability of the outer membrane of Gram-negative bacteria cells have been linked with resistance development. It has been hypothesized that encapsulation of drugs in niosomes could provide a stealth effect, enhance internalization by bacteria cells, and improve intracellular delivery to the cytoplasm [<xref rid="B7-pharmaceutics-17-00275" ref-type="bibr">7</xref>]. Generally, cationic niosomes are internalized faster and to a greater extent than negatively charged neutral particles due to stronger electrostatic attraction to the negatively charged cell membrane [<xref rid="B8-pharmaceutics-17-00275" ref-type="bibr">8</xref>].</p><p>Levofloxacin is the optical S-(-) isomer of the ofloxacin and a Biopharmaceutics Classification System (BCS) class 1 drug, which is highly soluble and highly permeable [<xref rid="B9-pharmaceutics-17-00275" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-17-00275" ref-type="bibr">10</xref>]. It has a broad spectrum of activity against Gram-positive, Gram-negative, and atypical organisms, such as Mycoplasma, Legionella, Mycobacterium, and Chlamydia [<xref rid="B11-pharmaceutics-17-00275" ref-type="bibr">11</xref>]. It is a major component of the antibacterial cocktails of <italic toggle="yes">H. pylori</italic> and is currently being repurposed via molecular modification as an anticancer agent [<xref rid="B12-pharmaceutics-17-00275" ref-type="bibr">12</xref>]. One of the main mechanisms by which bacteria develop resistance to antimicrobial agents is through the evolution of cellular structures that prevent drug permeation [<xref rid="B2-pharmaceutics-17-00275" ref-type="bibr">2</xref>,<xref rid="B13-pharmaceutics-17-00275" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00275" ref-type="bibr">14</xref>]. Although levofloxacin, a Biopharmaceutics Class 1 drug, is highly soluble and highly permeable [<xref rid="B9-pharmaceutics-17-00275" ref-type="bibr">9</xref>], bacteria are becoming increasingly resistant to the drug by efflux pump amplification and porin pathway blockade. Its resistance potency loss portends a major setback to the fight against peptic and duodenal ulcers and their potential progression to gastroduodenal carcinoma [<xref rid="B15-pharmaceutics-17-00275" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00275" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-00275" ref-type="bibr">17</xref>]. Approaches to levofloxacin formulation for enhanced intracellular delivery involve the use of lipid nanoparticles [<xref rid="B18-pharmaceutics-17-00275" ref-type="bibr">18</xref>], silica-based mesoporous materials [<xref rid="B19-pharmaceutics-17-00275" ref-type="bibr">19</xref>], and nanocarriers [<xref rid="B20-pharmaceutics-17-00275" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00275" ref-type="bibr">21</xref>].</p><p>In a previous study, we investigated formulations of select fluoroquinolones (norfloxacin, ciprofloxacin, gatifloxacin, and levofloxacin) in niosomes [<xref rid="B3-pharmaceutics-17-00275" ref-type="bibr">3</xref>,<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>]. In vitro testing against ciprofloxacin-resistant bacterial strains showed at least a two-fold increase in potency [<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>]. It appears that there is a lack of literature information on the mechanisms of biodistribution of levofloxacin niosomes in vivo. This study was designed to investigate the in vivo pharmacokinetics (PK) of an optimized niosomal formulation of levofloxacin in rats following intraperitoneal administration. The aim was to determine the pharmacokinetic parameters and any impact of niosomes on in vivo distribution of levofloxacin in rats.</p></sec><sec id="sec2-pharmaceutics-17-00275"><title>2. Materials and Methods</title><p>Span 60, ultrapure cholesterol, dihexadecyl phosphate (DCP), and levofloxacin were obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Other chemicals and reagents were obtained from Millipore Sigma (St. Louis, MO, USA) and were used without further treatment.</p><sec id="sec2dot1-pharmaceutics-17-00275"><title>2.1. Ethical Approval and Declaration</title><p>The study protocol was approved by the Department of Graduate Studies, University of the West Indies, St. Augustine, Trinidad and Tobago. The application for animal research was approved by the Animal Ethics Committee, Faculty of Medical Sciences, University of the West Indies. The research was conducted using Sprague Dawley rats. Protocols for animal handling followed the Principles of Laboratory Animal Care (LAC) and the Institutional Animal Care Committee (IACC) and in accordance with the National Institutes of Health&#x02019;s &#x0201c;Guide for the Care and Use of Laboratory Animals&#x0201d; (NIH publication no. 8623).</p></sec><sec id="sec2dot2-pharmaceutics-17-00275"><title>2.2. Experimental Design for Niosome Formulation</title><p>The input variables were entered into the Fusion One Design of Experiment (DoE) module as follows&#x02014;Design wizard mode: user interactive; design type: two levels (full factorial); number of internal blocks: 1; blocking strategy: no blocking; center point level settings: CHOL, 10; SAA, 10; DCP, 3.75, and variable level settings: CHOL (mM), 5.0 &#x0003c; CHOL &#x0003c; 15.0; SAA (mM), 5 &#x0003c; SAA &#x0003c; 15; DCP (mM%), 2.5 &#x0003c; DCP &#x0003c; 15. The layout of treatment parameters is shown in <xref rid="pharmaceutics-17-00275-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot3-pharmaceutics-17-00275"><title>2.3. Niosome Preparation and Characterization</title><p>Niosomes were prepared following the previously reported and optimized formulation comprising cholesterol, sorbitan monostearate (Span 60), and dihexadecyl phosphate (dicetylphosphate) in the molar ratio of 9.5:9.5:1, respectively, using the thin film hydration method [<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00275" ref-type="bibr">23</xref>]. Niosomes containing levofloxacin were prepared using surfactant (Span 60), cholesterol, and dicetylphosphate in varying molar ratios determined by Design of Experiment (DoE Fusion One software). The layout of factor combinations is shown in <xref rid="pharmaceutics-17-00275-t001" ref-type="table">Table 1</xref>. The thin film hydration and post-preparation handling procedures, previously reported in our lab [<xref rid="B3-pharmaceutics-17-00275" ref-type="bibr">3</xref>,<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>], were used. Hydrated pro-niosomes were ultra-sonicated for 6 min using a 20% amplification setting at 25 &#x000b0;C. The resulting colloidal dispersion was washed twice with phosphate-buffered saline and lyophilized. The lyophilized powder was stored in an air-tight, light-protective vial until used for further experimentation.</p><sec id="sec2dot3dot1-pharmaceutics-17-00275"><title>2.3.1. Characterization of NiosomesScanning Electron Microscope (SEM) of Niosomes</title><sec><title>Scanning Electron Microscope (SEM) of Niosomes</title><p>SEM analysis was performed at the George Washington University (GW) Nanofabrication and Imaging Center. To determine the size of the particles, all lyophilized compounds were mounted on aluminum stubs using carbon tape for SEM analysis. Imaging was performed using an in-lens FEI Teneo FEG SEM (Thermo Fisher, Allentown, PA, USA). High-resolution images were acquired under high-vacuum conditions, with a voltage of 2 kV, a beam landing current of 25 pA, and a working distance of 3.9 mm. The horizontal field width was set to 11.8 &#x000b5;m, and the pixel size was 1.93 nm. A dwell time of 1 &#x000b5;s was used, along with a resolution of 6000 &#x000d7; 6000 pixels for each SEM image. No coating was applied during these analyses.</p></sec><sec><title>Transmission Electron Microscopy</title><p>A total of 5 mL of nanoparticle suspension was applied for 5 min onto formvar/carbon-coated 200 mesh copper grids (Electron Microscopy Sciences, Hatfield, PA, USA) that were glow discharged (20 mA for 60 s) right before use. EVs were negatively stained with 1% uranyl acetate (Electron Microscopy Sciences) for 2 min and air-dried before imaging. A FEI Talos F200X transmission electron microscope (Electron Microscopy Sciences, Hatfield, PA, USA) operated at 200 kV was used. Images were acquired with a Thermo Scientific Ceta 16M CMOS camera (Thermo Fisher Scientific, Washington, DC, USA).</p></sec><sec><title>Vesicle Size, Polydispersity Index (PDI), and Zeta Potential</title><p>The hydrodynamic size, size distribution, and polydispersity index (PDI) of the niosomes were determined using a 90Plus particle Size Analyzer (Brookhaven Instruments, NY, USA). About 100 &#x000b5;L of freshly prepared niosomes was diluted to 2 mL in deionized water, loaded into culverts, and analyzed following the manufacturer&#x02019;s protocols. The surface charge (Zeta potential) was also determined using the 90Plus particle Size Analyzer.</p></sec></sec></sec><sec id="sec2dot3dot2-pharmaceutics-17-00275"><title>2.3.2. Assay of Niosome Drug Content</title><p>Amounts of drugs in starting, intermediate, and finished niosomes were analyzed using validated methods on an Agilent 1260 Infinity HPLC machine.</p><sec><title>HPLC Method Development</title><p>The HPLC system comprised the Agilent 1260 Infinity II LC Gradient DAD System, incorporating a gradient pump with degasser (max. pressure 600 bar), autosampler, and column oven and equipped with OpenLab CDS Workstation PC Bundle (Agilent Technologies, Savage, MD, USA). The column was Poroshell 120 EC-C18 4.6 &#x000d7; 100 mm, 2.7 &#x003bc;m. The mobile phase comprised acetonitrile: water, each with 0.75% trifluoro acetic acid (TFA) operated in gradient mode. The injection volume was 20 &#x003bc;L, and the column temperature was at 35 &#x000b0;C. The system was validated for specificity, repeatability, accuracy, and precision following USP specifications.</p><p>The drug contents of formulated niosomes (encapsulation efficiency, EE) were calculated according to the following formula:<disp-formula>EE = (W Encapsulated/W total) &#x000d7; 100%</disp-formula></p></sec><sec><title>In Vitro Dissolution of Drug from Niosomes</title><p>The dialysis tube method previously reported [<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>] was used with modification to determine drug dissolution from lyophilized niosome powder. An amount of niosomes equivalent to 5 mg of the drug was placed in a dialysis tube. The tube was suspended in an external reservoir containing 50 mL of phosphate buffer saline (pH 7.4) maintained at 37 &#x000b1; 1 &#x000b0;C and subjected to continuous oscillatory stirring motion at 50 rpm. Aliquots of 2 mL were withdrawn at specified time intervals and replaced with fresh medium equilibrated to 37 &#x000b0;C. The amount of drug in each aliquot was determined by the validated HPLC method.</p></sec></sec><sec id="sec2dot4-pharmaceutics-17-00275"><title>2.4. Design of Bioavailability Study</title><p>The principle of 3Rs (Reduction, Refinement, and Replacement) [<xref rid="B24-pharmaceutics-17-00275" ref-type="bibr">24</xref>] guided the Animal Ethics Committee in approving twelve rats for the study protocol. A non-crossover, one-phase parallel experimental design was used. Sprague Dawley rats 6&#x02013;8 weeks old, weighing between 200 and 250 g, were obtained from the School of Veterinary Medicine, University of the West Indies. The animals were randomly assigned to 2 groups (n = 6) and were allowed to acclimatize to the local conditions for seven days before any experimental work was performed. Group 1 animals were given the conventional (pure) drug, whilst group 2 animals were given an equivalent dose of the drug entrapped in niosomes. Levofloxacin (&#x0003e;98% pure HPLC, Sigma Aldrich, Oakville, ON, Canada) solution in phosphate-buffered saline (PBS) was administered intraperitoneally (i.p.) in the left lower quadrant at a dose of 7.5 mg/kg, as previously reported [<xref rid="B9-pharmaceutics-17-00275" ref-type="bibr">9</xref>], using a 23gauge needle. The tail was cleaned with chlorhexidine gluconate, followed by an alcohol prep pack, and allowed to dry whilst the animal was restrained. The tail was snipped approximately 1&#x02013;2 mm above the tip with a pair of sterile scissors and was massaged gently from top to bottom whilst blood was collected in sterile Eppendorf tubes. Blood was collected at time points 0, &#x000bd;, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours after the drug was administered. The total volume of blood collected during a 24 h period was limited to &#x02264;7.5% of the total circulating volume (estimated average of 64 mL/kg), in accordance with the NIH Animal Research Advisory Committee (ARAC) Guidelines (National Institutes of Health (US) [<xref rid="B25-pharmaceutics-17-00275" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot5-pharmaceutics-17-00275"><title>2.5. Sample Preparation for HPLC Analysis</title><p>Eppendorf tubes containing blood samples were allowed to stand for 30 min. Blood samples were then centrifuged at 5000 rpm for 10 min. The serum was then carefully siphoned using a micropipette. A micropipette was used to transfer 40 &#x000b5;L of serum to a clean, dry Eppendorf tube (1.5 mL), followed by 120 &#x000b5;L of methanol to precipitate protein content. The resulting mixture was vortexed for one minute and then centrifuged for 10 min at 10,000 rpm. The supernatant was collected and stored in clean, dry Eppendorf tubes at &#x02212;80 &#x000b0;C until used for analysis.</p><p>To obtain blank serum from rat blood for HPLC analysis, rats were euthanized using 150 mg/kg i.p. pentobarbital injection [<xref rid="B26-pharmaceutics-17-00275" ref-type="bibr">26</xref>]. The rodent was placed lying on its back and checked for pedal reflex to ensure the animal could not feel pain. Blood was drawn by cardiac puncture. With the bevel facing upwards, the needle was inserted to the left of the animal&#x02019;s xiphoid process (base of the sternum), directing the needle towards the chin at a 30&#x02013;45&#x000b0; angle. After the needle tip penetrated the skin, the syringe plunger was gently pulled back to create slight negative pressure. The needle was advanced until blood was withdrawn. If unable to withdraw blood, the needle was slowly withdrawn while maintaining the negative pressure on the syringe until the needle was nearly but not completely withdrawn. The needle was then redirected in a slightly different direction. Blood was placed in a sterile tube and allowed to stand for 30 min. Blood samples were then centrifuged at 5000 rpm for 10 min. The supernatant was removed and placed in sterile glass tubes. Methanol was added to serum in a ratio of 3:1 for protein precipitation. The resulting mixture was vortexed for one minute and centrifuged for 10 min at 10,000 rpm. The supernatant was collected and stored in clean, dry Eppendorf tubes at &#x02212;80 &#x000b0;C until used for analysis. To prepare the sample for analysis, 20 &#x000b5;L of serum was placed in a clean, dry Eppendorf tube using a micropipette. Forty microliters (40 &#x000b5;L) of methanol was added. The contents were vortexed for one minute and then centrifuged at 10,000 rpm for 10 min. The supernatant was removed and loaded in an HPLC autosampler tray, from which 20 &#x000b5;L was injected during the analysis. HPLC analytical parameters were as described under <xref rid="sec2dot3dot2-pharmaceutics-17-00275" ref-type="sec">Section 2.3.2</xref>. above.</p></sec><sec id="sec2dot6-pharmaceutics-17-00275"><title>2.6. Treatment and PK Analysis of Plasma Data</title><p>HPLC data were entered into Gastroplus PK<sup>TM</sup> (Simulations Plus, Inc., Lancaster, CA, USA) modeling and simulation software. The data obtained from the pharmacokinetic analysis of serum samples represented the drug concentrations in plasma (Cp) at various time points. The Cp vs. time data were entered in the GastroPlus&#x02122; menu, and the non-compartment analysis (NCA) was conducted.</p><p>The individual weight of each animal was then entered into the software, and pharmacokinetic modeling was determined for one, two, and three compartmental models. The software used the Hooke and Jeeves Pattern search [<xref rid="B27-pharmaceutics-17-00275" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00275" ref-type="bibr">28</xref>] with the error weighting set at 1/Yhat<sup>2</sup>. The software was able to generate solutions for non-compartment analysis (NCA) and one-, two-, and three-compartment models. This data analysis incorporated model fitness algorithms of the Akaike information criterion (AIC) [<xref rid="B28-pharmaceutics-17-00275" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00275" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00275" ref-type="bibr">30</xref>] and Schwarz criterion (SC) [<xref rid="B31-pharmaceutics-17-00275" ref-type="bibr">31</xref>] according to the following equations:<disp-formula>AIC = (#Pts) &#x000d7; Log(Obj) + 2(#Parameters)<label>(1)</label></disp-formula><disp-formula>SC = (#Pts) &#x000d7; Log(Obj) + (#Parameters) &#x000d7; (Log(#Pts))<label>(2)</label></disp-formula></p><p>The best model was reported by each algorithm together with estimates of errors (residuals).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00275"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00275"><title>3.1. Niosome Physicochemical Properties and Encapsulation Efficiency</title><p>The SEM images of levofloxacin niosomes are shown in <xref rid="pharmaceutics-17-00275-f001" ref-type="fig">Figure 1</xref>A,B. Encapsulation efficiency (EE) ranged from 9.5% (Formulation #6) to 34.2% (Formulation #11), PDI ranged from 0.216 (Formulation 1) to 0.392 (Formulation 12) while vesicle size ranged from 203 nm (Formulation #1) to 783.1 (Formulation #10). The goal of a good nanoencapsulation delivery system is to minimize vesicle size (for stability and cellular internalization via biological membranes) and to maximize EE and polydispersity index. Also, a positive Zeta potential has been suggested but is still subject to controversy. <xref rid="pharmaceutics-17-00275-t002" ref-type="table">Table 2</xref> shows that the regression of vesicle size on vesicle-forming input variables (CHOL and Span 60) was not statistically significant (<italic toggle="yes">p</italic> = 0.066). This indicates that other variables, including charge inducer and drug molecules, might be influencing vesicle formation. <xref rid="pharmaceutics-17-00275-t003" ref-type="table">Table 3</xref> shows the model ranking of input variables in the order of SP60 &#x0003e; CHOL &#x0003e; SP60-CHOL interaction). Data from the screening experiments were inputted into the DoE Optimizer module. The predicted optimized formulation for achieving particle size minimization was prepared in triplicate, and the particle size was determined. Model verification was performed by comparing the vesicle sizes of the suggested optimized solution obtained from laboratory data to the predicted vesicle size (<xref rid="pharmaceutics-17-00275-t004" ref-type="table">Table 4</xref>). The average vesicle size and PDI of the experimental formulation were 330.92 (&#x000b1;177.19) and 0.273 (&#x000b1;0.06), respectively, compared to the predicted values of 329.16 nm and 0.286. The difference between experimental and predicted vesicle size and PDI, respectively, were not statistically significant (<italic toggle="yes">p</italic> &#x0003e; 0.05). The observed mean encapsulation efficiency (EE) was 19.56 (&#x000b1;9.14). Preparation of test niosomes using DoE Optimizer recommended factors combination produced niosomes with an average size of 329.16 nm &#x000b1; 18.0 (SE), PDI of 0.286 &#x000b1; 0.014 (SE), EE of 30.74%, and Zeta potential of 21.72 &#x000b1; 0.54 (SE), each of which fell within the predicted (&#x02212;/+)2 Sigma range of encapsulation efficiency (<xref rid="pharmaceutics-17-00275-t004" ref-type="table">Table 4</xref>). This was used in animal studies.</p><p>Typical plots of size distribution and Zeta potential of niosomes are shown in <xref rid="pharmaceutics-17-00275-f002" ref-type="fig">Figure 2</xref>A,B.</p><p>The impact of input variables on niosome characteristics is predicted by the Equations (3) to (5):<disp-formula>Vesicle size (nm) = + 322.595 + 73.703(CHOL) &#x02212; 76.230(CHOL &#x000d7; SP60) + 97.330(SP60 &#x000d7; DCP)<label>(3)</label></disp-formula><disp-formula>EE (%) = + 27.428 + 4.318 (SP60 &#x000d7; X3)<label>(4)</label></disp-formula><disp-formula>Zeta = &#x02212;20.724 + 19.180(SP60) + 34.761(SP60) + 32.920(CHOL &#x000d7; SP60)<label>(5)</label></disp-formula></p><p>The interrelationship of niosome formers on vesicle size, encapsulation efficiency, and Zeta potential are shown in the response surface graphs in <xref rid="pharmaceutics-17-00275-f003" ref-type="fig">Figure 3</xref>A, B, and C, respectively.</p><p>The response surface graphs of niosome properties and input variables are shown in <xref rid="pharmaceutics-17-00275-f003" ref-type="fig">Figure 3</xref>B,C. Generally, increasing the ratio of cholesterol to Span 60 causes a significant decrease in the average particle size.</p></sec><sec id="sec3dot2-pharmaceutics-17-00275"><title>3.2. HPLC Analytical Method Parameters</title><p>The calibration samples of levofloxacin at different concentrations were prepared and analyzed on HPLC using parameters described in <xref rid="sec2dot3dot2-pharmaceutics-17-00275" ref-type="sec">Section 2.3.2</xref>. The chromatogram obtained using a mobile phase of water: acetonitrile (+0.75% trifluoro acetic acid, TFA) in gradient mode sowed levofloxacin elution at an average retention time of 5.8 (&#x000b1;0.047) minutes (<xref rid="pharmaceutics-17-00275-f004" ref-type="fig">Figure 4</xref>A). The peak area obtained for each sample was plotted against the respective concentration (<xref rid="pharmaceutics-17-00275-f004" ref-type="fig">Figure 4</xref>B). The equation of the line (Equation (1)) obtained from the calibration curve was as follows:<disp-formula>Peak Area = 294.06 &#x000d7; Conc &#x02212; 54.583<label>(6)</label></disp-formula></p><p>The correlation between peak area versus concentration plot was near perfect linearity with R&#x000b2; = 0.9987. The parameters of Eqn. 6 were used to convert areas of chromatograms obtained for the analytes to drug concentrations and independently confirmed with intermittent analysis of known concentrations of reference samples interspersed between each set of analytes run on HPLC. The HPLC analytical parameters are shown in <xref rid="pharmaceutics-17-00275-t005" ref-type="table">Table 5</xref>. The dependence of the chromatogram&#x02019;s AUC (mAU/s) on analyte concentration in assayed samples is reflected by the very high regression coefficient (R<sup>2</sup> &#x0003e; 0.99). The validity of the analytical method is supported by the high accuracy of 99.7% (USP range: 85&#x02013;155%) and mean recovery of 97.9% (USP range: 85&#x02013;115%). The stability of the analytical method is shown by the intra-day and inter-day data shown in <xref rid="pharmaceutics-17-00275-f005" ref-type="fig">Figure 5</xref>. The intra-day and inter-day validation runs on HPLC showed variations of less than 6.12% and reproducibility with a relative error of less than 2.5% (<xref rid="pharmaceutics-17-00275-t006" ref-type="table">Table 6</xref>). The upper and lower limits (<xref rid="pharmaceutics-17-00275-f005" ref-type="fig">Figure 5</xref>) are within 95% and 110%.</p></sec><sec id="sec3dot3-pharmaceutics-17-00275"><title>3.3. Drug Dissolution from Niosomes</title><p>The dissolution profiles of levofloxacin from screening experiments and optimized niosome formulation with equivalent encapsulation efficiencies are shown in <xref rid="pharmaceutics-17-00275-f006" ref-type="fig">Figure 6</xref>. Optimized formulation showed a slightly higher release rate until about 5 h. Less than 80% was released in 6 h, while about 100% was released in 8 h from both formulations. Niosome encapsulation effectively protected the drug from rapid release, typical of the pure drug from conventional dosage forms. Niosome formulation could extend the short half-life of pure levofloxacin.</p></sec><sec id="sec3dot4-pharmaceutics-17-00275"><title>3.4. Non-Compartmental Analysis (NCA) in GastroPlus&#x02122;</title><p>Results of data treatment in the PK module of the Gastroplus modeling and simulation software indicated the weighted sum of squared errors = 7.7402 &#x000d7; 10<sup>&#x02212;1</sup> and a weighting of 1/Yhat<sup>2</sup>. <xref rid="pharmaceutics-17-00275-f007" ref-type="fig">Figure 7</xref>A&#x02013;C display the results of levofloxacin concentration versus time (Cp vs. t), log-transformed Cp vs. t, and the plots of residuals, respectively, for levofloxacin formulation in niosomes. Similarly, <xref rid="pharmaceutics-17-00275-f008" ref-type="fig">Figure 8</xref>A&#x02013;C display the respective results of pure drug levofloxacin following intraperitoneal administration in rats. Plots in <xref rid="pharmaceutics-17-00275-f008" ref-type="fig">Figure 8</xref>A,B show discernible bi-exponential profiles of the respective Cp versus t and log Cp versus t plots, which are reflective of the two-compartment open model. The comparative bioavailability profiles of levofloxacin and its niosomes are shown in <xref rid="pharmaceutics-17-00275-f009" ref-type="fig">Figure 9</xref>.</p><p>Non-compartmental PK parameters are useful for predicting biodisposition patterns of drug molecules from delivery systems into and outside of the biological system. The area under the concentration versus time plot (AUC) is an indication of the rate and extent of drug exposure to the body. AUMC is the area under the first moment curve. It is obtained as the product of concentration and the time it was obtained. When AUMC is divided by the AUC, the mean residence time (MRT) is obtained. MRT is an index of how long the drug molecule stays at different sites in the body. As shown in <xref rid="pharmaceutics-17-00275-t007" ref-type="table">Table 7</xref>, AUC, AUMC, and MRT values are higher for niosomes than for levofloxacin. The comparative values of MRT is also shown in <xref rid="pharmaceutics-17-00275-f010" ref-type="fig">Figure 10</xref>. Conversely, the rate of removal of drugs from the body (clearance, Cl) is slower for niosomes than for the pure drug, indicating the ability of niosomes to sustain the intravascular residence of the embedded drug.</p><p>The algorithmic search in Gastroplus for the most fitting PK model (using Hooke and Jeeves patterns search [<xref rid="B27-pharmaceutics-17-00275" ref-type="bibr">27</xref>] and objective weighting of 1/Yhat<sup>2</sup>) indicated that both Akaike information criterion (AIC) [<xref rid="B29-pharmaceutics-17-00275" ref-type="bibr">29</xref>] and Schwartz criterion (SC) [<xref rid="B30-pharmaceutics-17-00275" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00275" ref-type="bibr">31</xref>] support the one-compartment as the preferred model for PK of drug in niosomes and two-compartment as the preferred model for the PK of pure levofloxacin.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00275"><title>4. Discussion</title><sec id="sec4dot1-pharmaceutics-17-00275"><title>4.1. Niosome Formulation and Characterization</title><p>Span 60 (SP60) was selected as a niosome-forming, non-ionic, lipid-soluble surfactant, cholesterol (CHOL) was used as a membrane stabilizer, and dihexadecyl phosphate (DCP) was used as a charge inducer for the prepared niosomes based on our previous studies [<xref rid="B3-pharmaceutics-17-00275" ref-type="bibr">3</xref>,<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>]). Using a 2<sup>3</sup> factorial experiment with four center points (total formulation = 12), levels of SP60, CHOL, and DCP for the control niosomes were screened. Input data from the screening experiment (Span 60/CHOL/DCP) and the corresponding output variables were inputted into the Optimizer module, and the predicted responses generated are shown in <xref rid="pharmaceutics-17-00275-t004" ref-type="table">Table 4</xref>. The Optimizer recommended variable molar levels (Span 60/CHOL/DCP, 15:24:9) were used to prepare the niosomes used in the BA study.</p><p>The size, PDI, and Zeta potential of niosomes are determined by the formulation ingredients, and the media in the niosomes are suspended [<xref rid="B32-pharmaceutics-17-00275" ref-type="bibr">32</xref>]. Zeta potential and particle size affect the thermodynamic properties of the niosomes. Because the smaller-sized niosomes have a larger surface-to-volume ratio, they tend to be more thermodynamically stable. The particle size distribution and polydispersity index (PDI) of niosomes can affect the processability, bulk properties, product appearance, and biological performance of the product [<xref rid="B32-pharmaceutics-17-00275" ref-type="bibr">32</xref>]. Thus, reliable and reproducible analytical procedures for niosomes&#x02019; mean vesicle diameter, surface charge, and heterogeneity are important fundamental quality control product parameters. The small niosome sizes and the high value of Zeta potential imply good stability of the colloidal dispersion, while the reasonably high %EE indicates the ability to deliver therapeutic concentration of niosomes intravascularly via i.p. injections. Cholesterol can enhance the bilayer hydrophobicity by its aliphatic chain aligning parallel to the hydrocarbon chains of the amphiphilic surfactant (Span 60) and its hydroxyl group of the sterol moiety forming a hydrogen bond with the ester group in Span 60. This alignment will cause a decrease in surface free energy, thereby promoting vesicle size reduction. Thus, vesicle size increases with the proportion of Span 60 and decreases with that of cholesterol (<xref rid="pharmaceutics-17-00275-f003" ref-type="fig">Figure 3</xref>A), while encapsulation efficiency increases with the proportion of Span 60 and decreases with cholesterol for hydrophilic drugs like levofloxacin (<xref rid="pharmaceutics-17-00275-f003" ref-type="fig">Figure 3</xref>B).</p></sec><sec id="sec4dot2-pharmaceutics-17-00275"><title>4.2. PK Modeling and Analysis</title><p>From the data generated for the NCA in <xref rid="pharmaceutics-17-00275-t006" ref-type="table">Table 6</xref>, the AUC, AUMC, MRT, Cl, and Vss are all above the 125% range for bioequivalence. The coefficient of variation (CV) accompanying various parameter values of the compartmental models in <xref rid="pharmaceutics-17-00275-t007" ref-type="table">Table 7</xref>, <xref rid="pharmaceutics-17-00275-t008" ref-type="table">Table 8</xref> and <xref rid="pharmaceutics-17-00275-t009" ref-type="table">Table 9</xref> is the measure of errors or residuals for which the respective models cannot account. Thus, the higher the CV values, the less powerful the model is in representing the PK profiles for the biodisposition of the drug. As shown in <xref rid="pharmaceutics-17-00275-t007" ref-type="table">Table 7</xref>, <xref rid="pharmaceutics-17-00275-t008" ref-type="table">Table 8</xref> and <xref rid="pharmaceutics-17-00275-t009" ref-type="table">Table 9</xref>, CV values for a given parameter increase with an increase in the number of the model&#x02019;s compartments. On the other hand, R<sup>2</sup> is a measure of the model&#x02019;s strength correlating log plasma concentration with time. The higher the value (i.e., the closer it approached perfect linearity with R<sup>2</sup> = 1), the stronger and more predictive the model. For the one-compartment model, R<sup>2</sup> = 0.418 for niosomes and R<sup>2</sup> = 0.335 for unencapsulated drugs. When escalated to the two-compartment model, however, R<sup>2</sup> = 0.418 for niosomes, while R<sup>2</sup> = 0.5749 for pure drug. Unlike the simple linear models, the Gastroplus platform has a more integrative model search capability involving the use of powerful algorithms of AIC and SC criteria with appropriate error weighting.</p><p>The summary Cp versus t plots of niosomes and non-encapsulate drugs are shown in <xref rid="pharmaceutics-17-00275-f009" ref-type="fig">Figure 9</xref>, while their corresponding AUC of niosomes and pure levofloxacin are shown in <xref rid="pharmaceutics-17-00275-t007" ref-type="table">Table 7</xref>, <xref rid="pharmaceutics-17-00275-t008" ref-type="table">Table 8</xref> and <xref rid="pharmaceutics-17-00275-t009" ref-type="table">Table 9</xref>. Bioequivalence of a given product is conferred if the mean bioavailability of the test product under consideration is within 80&#x02013;125% of the reference formulation. From the perspective of pharmacokinetic modeling, the FDA 2003 guidance indicated that other parameters, such as AUC<sub>(0&#x02013;&#x0221e;)</sub>, AUC<sub>(0&#x02013;tlast)</sub>, and C<sub>max</sub>, should also be considered [<xref rid="B33-pharmaceutics-17-00275" ref-type="bibr">33</xref>]. The values of AUC, AUMC, and MRT were all significantly higher for the niosomal formulation than for the unentrapped drug (<xref rid="pharmaceutics-17-00275-t007" ref-type="table">Table 7</xref> and <xref rid="pharmaceutics-17-00275-t008" ref-type="table">Table 8</xref>). The decreased volume of distribution, decreased clearance, and enhanced MRT and AUC are positive outcomes of niosomal encapsulation, which is indicative of the potential of niosomes to increase the drug&#x02019;s therapeutic efficacy whilst concurrently minimizing its adverse effects. While the one-compartment behavior of levofloxacin niosomes and the corresponding increase of MRT and reduced CL and Vss cannot be easily explained, it appears that the niosomal formulation prevented rapid drug release and released it in a sustained manner. Therefore, the relative bioavailability and the MRT of the niosome-encapsulated drug were increased above those of unencapsulated drug molecules.</p><p>Fluoroquinolones generally have a superior ability to penetrate tissues [<xref rid="B34-pharmaceutics-17-00275" ref-type="bibr">34</xref>] than other antibiotics and can penetrate organelles like macrophages and neutrophils to accentuate bactericidal activity [<xref rid="B35-pharmaceutics-17-00275" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-00275" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00275" ref-type="bibr">37</xref>]. Analysis of the data generated for the one-compartment model of levofloxacin shows several parameter differences between the niosome-encapsulated formulations and the conventional pure drug. All parameters tested were out of the bioequivalence range, indicating significant differences in their pharmacokinetic parameters. Differences in all parameters tested were significant at a 95% confidence interval, except for MRT, Vd, and t<sub>1/2.</sub> Even though the MRT, Vd, and t<sub>1/2</sub> showed no significant difference, the MRT for the niosome formulation (40.62 h) was 1.64 times higher than that of the unentrapped conventional formulation (24.66 h). The same was observed for the t<sub>1/2</sub> of the niosome-entrapped drug (28.66 h), which shows a half-life of 1.64 X than that of the unentrapped drug (17.09 h). Thus, the niosome-entrapped drug showed a higher effect on all other parameters than the unentrapped drug. The only possible reason for this difference was the drug delivery system employed. Encapsulation in niosomes seems to restrict drug distribution, enhance plasma levels, and allow for sustained release of drug molecules from the construct. In the two-compartment model (<xref rid="pharmaceutics-17-00275-t009" ref-type="table">Table 9</xref>), only the values of Vc and C<sub>max</sub> were bioequivalent, with all other parameters falling outside of the stipulated 80&#x02013;125% range. The data, however, were not significantly different, as can be seen from the &#x0201c;t&#x0201d; values, as well as the p values generated for these data (<xref rid="pharmaceutics-17-00275-t009" ref-type="table">Table 9</xref>). Progression to the three compartmental analysis (<xref rid="pharmaceutics-17-00275-t010" ref-type="table">Table 10</xref>) resulted in PK parameters losing reliability as the coefficient of variation increased dramatically.</p><p>The Hooke and Jeeves pattern search [<xref rid="B27-pharmaceutics-17-00275" ref-type="bibr">27</xref>] also showed a difference in the release and pharmacokinetic characteristics of the two formulations. The patterns shown in <xref rid="pharmaceutics-17-00275-f007" ref-type="fig">Figure 7</xref>A,B indicate that niosome formulation shows a linear pattern of drug release. The initial post-absorption rate of drug release from the niosomal formulation was much slower and more sustained than those from the conventional free drug (<xref rid="pharmaceutics-17-00275-f008" ref-type="fig">Figure 8</xref>A,B). The logarithmic display for niosome (<xref rid="pharmaceutics-17-00275-f007" ref-type="fig">Figure 7</xref>B) and conventional drug (<xref rid="pharmaceutics-17-00275-f008" ref-type="fig">Figure 8</xref>B) show a clear difference in release pattern as the niosome profile is linear compared to the nonlinear profile of the conventional drug. The plot of residuals for the niosome-treated animals (<xref rid="pharmaceutics-17-00275-f007" ref-type="fig">Figure 7</xref>C) showed an even distribution around the horizontal axis that supports a linear profile of drug release. This even distribution was not seen in the plot for the conventional formulation (<xref rid="pharmaceutics-17-00275-f008" ref-type="fig">Figure 8</xref>C). The average Cp vs. time profiles for rats administered levofloxacin niosomes and those with pure levofloxacin are shown in <xref rid="pharmaceutics-17-00275-f009" ref-type="fig">Figure 9</xref>. Similar findings have been reported by other studies in the literature. Ruckmani et al. (2010) [<xref rid="B38-pharmaceutics-17-00275" ref-type="bibr">38</xref>] and Ammar et al. (2017) [<xref rid="B39-pharmaceutics-17-00275" ref-type="bibr">39</xref>] showed that niosome entrapment of the drugs enhanced the AUC, MRT, and t<sub>1/2</sub>. Feitosa et al. (2022) [<xref rid="B40-pharmaceutics-17-00275" ref-type="bibr">40</xref>] developed a niosomal formulation of doxycycline using Span 60/Tween 60 and cholesterol via the modified thin hydration method. The average size of the final formulation was 281.9 nm, and encapsulation efficiency (EE) was 72.1%. A significantly lower minimum inhibitory concentration (MIC) against different Gram-positive and Gram-negative bacteria was reported, indicating higher antibacterial activity of doxycycline niosomes than that of the free drug [<xref rid="B4-pharmaceutics-17-00275" ref-type="bibr">4</xref>,<xref rid="B40-pharmaceutics-17-00275" ref-type="bibr">40</xref>].</p><p>To determine the model that best fit the drug exposure in the rats, the model search was extended from non-compartmental (purely mechanistic) to physiologic models depicting the body compartments into one, two, or three, depending on the rate of perfusion and rapidity of equilibration between plasma (central compartment) and various organs (rapidly equilibrating organs and tissues) [<xref rid="B41-pharmaceutics-17-00275" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-00275" ref-type="bibr">42</xref>]. While noting that PK models cannot indicate the absolute physiological or anatomical location of drug molecules as they traverse the body of an animal [<xref rid="B43-pharmaceutics-17-00275" ref-type="bibr">43</xref>], a close approximation of one model relative to another may provide the most accurate representation of drug exposure systemically. Presently, many drugs need to be administered at sufficient doses to obtain the required dose at the desired site of action, which may often be outside of the plasma compartment. The PK parameters selected based on the most predictive model could be advantageous in the choice of delivery design that would provide the most efficient drug dosing. For instance, as was previously reported [<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>], a 50% reduction in MIC/MBC of some fluoroquinolone niosomes (including levofloxacin, gatifloxacin, and ciprofloxacin) on drug-resistant strains of <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">E. coli</italic>, and <italic toggle="yes">S. aureus</italic> could enable dose reduction if the PK parameters indicate that drug perfusion is actually enhanced by niosome encapsulation of the drug molecules. Therefore, the slower rate of distribution of niosome-encapsulated levofloxacin from plasma to the extravascular compartment (niosomes kz = 0.025; pure drug kz = 0.041) and the significantly higher mean residence time (MRT, <xref rid="pharmaceutics-17-00275-f010" ref-type="fig">Figure 10</xref>) suggest a high potential for the translation of the observed reduction in MIC/MBC in vitro to in vivo microenvironment.</p><p>Encapsulation in sub-microscopic particles generally has been associated with improved bioavailability. Until recently, liposomes have been used extensively to improve the pharmacokinetic profile of drugs for administration via different routes [<xref rid="B44-pharmaceutics-17-00275" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-00275" ref-type="bibr">45</xref>]. The results of those studies indicate the ability of the drug carrier to preserve the drug en route distribution channels to the plasma, protect it from the external environment, and preferentially deliver it to the site where its action is needed. These outcomes have inspired the FDA approval of some liposomal formulations for clinical use. However, the short in vivo fate of liposomes is a limiting factor, and studies have focused on improving its circulation time [<xref rid="B44-pharmaceutics-17-00275" ref-type="bibr">44</xref>]. Unlike liposomes, niosomes are cheaper to produce and do not require special storage and handling conditions. Hence, recent attention has been focused on niosomal drug delivery, as in this study. Taken together with our previous report [<xref rid="B22-pharmaceutics-17-00275" ref-type="bibr">22</xref>], this PK model analysis indicates that niosome encapsulation of levofloxacin by concentrating the drug in the intravascular compartment, preventing its binding to plasma protein, and preventing bacteria sensing of drug molecules that are enveloped in lipid vesicles (niosomes) has the potential to obviate resistance development, which is currently limiting the efficacy of the drug.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-00275"><title>5. Conclusions</title><p>Niosome formulation containing Span 60, cholesterol, and dihexadecyl phosphate at a 15:24:9 molar ratio produced encapsulation efficiency (EE) of 32.47%, mean hydrodynamic vesicle size of 320.19 nm (&#x000b1;18.0 nm), PDI of 0.316 &#x000b1; 0.014 (SE), and Zeta potential of 21.72 &#x000b1; 0.54 (SE), each of which fell within the predicted (&#x02212;/+)2 Sigma range. This optimized levofloxacin-loaded formulation was used for the BA studies in rats. All PK parameters tested were out of the bioequivalence range, indicating significant differences in pharmacokinetic parameters of nio-encapsulated and non-encapsulated levofloxacin. Differences in all parameters tested were significant at a 95% confidence interval, except for Vd and t<sub>1/2.</sub> The MRT for the niosome formulation (40.62 h) was 1.64 times higher than that of the unentrapped conventional formulation (24.66 h). The same was observed for the t<sub>1/2</sub> of the niosome-entrapped drug (28.66 h), which shows a half-life of 1.64 x than that of the unentrapped drug (17.09 h). Niosomes appear to protect levofloxacin en route into plasma, altering its pharmacokinetic profile by preventing its binding to plasma protein and increasing its residence time in the systemic circulation. This suggests significant potential for niosomal delivery of levofloxacin to intravascular bacteria. Taken together with our previous report, this PK model analysis indicates that niosome encapsulation of levofloxacin could prevent bacteria sensing of the drug molecules, thereby obviating resistance development, which is currently limiting the efficacy of the drug. Further studies are needed to confirm intracellular delivery and the delivery mechanisms of niosome-encapsulated levofloxacin into multi-drug-resistant bacterial cells.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge the gift of Gastroplus PK Modeling and Simulations software by Simulations Plus, Inc. (NASDAQ: SLP) 42505 10th Street West|Lancaster, CA 93534|United States.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.S.A., S.J. and L.P.P.; methodology, A.S.A., J.J. and S.J.; software, A.S.A. and S.K.A.; validation, A.S.A., S.J., S.K.A., K.A. and J.J.; formal analysis, A.S.A., K.A. and S.J.; investigation, S.J., J.J. and A.S.A.; resources, A.S.A., S.J. and J.J.; data curation, A.S.A., S.J. and K.A.; writing&#x02014;original draft preparation, S.J. and A.S.A.; writing&#x02014;review and editing, A.S.A., L.P.P. and S.K.A.; visualization, A.S.A.; supervision, A.S.A. and L.P.P.; project administration, A.S.A. and S.J.; funding acquisition, A.S.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Animal Ethics Committee, Faculty of Medical Sciences, University of the West Indies, and the Institutional Biosafety Committee of Howard University (IBC-2023-0015 of 10/18/2023).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available upon request from the corresponding author due to related studies that are ongoing and pending patent applications.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="left" valign="middle" rowspan="1" colspan="1">high-pressure liquid chromatography</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EE</td><td align="left" valign="middle" rowspan="1" colspan="1">encapsulation efficiency</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIC</td><td align="left" valign="middle" rowspan="1" colspan="1">Akaike information criterion </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BIC</td><td align="left" valign="middle" rowspan="1" colspan="1">Bayesian information criterion</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SC</td><td align="left" valign="middle" rowspan="1" colspan="1">Schwartz criterion </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRT</td><td align="left" valign="middle" rowspan="1" colspan="1">mean residence time</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vd</td><td align="left" valign="middle" rowspan="1" colspan="1">volume of distribution</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">t1/2</td><td align="left" valign="middle" rowspan="1" colspan="1">elimination half-life</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AUC</td><td align="left" valign="middle" rowspan="1" colspan="1">area under the plasma concentration versus time plot</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AUMC</td><td align="left" valign="middle" rowspan="1" colspan="1">area under the first moment curve</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCS</td><td align="left" valign="middle" rowspan="1" colspan="1">Biopharmaceutics Classification System</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHOL</td><td align="left" valign="middle" rowspan="1" colspan="1">cholesterol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCP</td><td align="left" valign="middle" rowspan="1" colspan="1">dihexadecyl phosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAA</td><td align="left" valign="middle" rowspan="1" colspan="1">surface active agent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SEM</td><td align="left" valign="middle" rowspan="1" colspan="1">scanning electron microscope</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TEM</td><td align="left" valign="middle" rowspan="1" colspan="1">transmission electron microscope</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDI</td><td align="left" valign="middle" rowspan="1" colspan="1">polydispersity index</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cl</td><td align="left" valign="middle" rowspan="1" colspan="1">clearance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vss</td><td align="left" valign="middle" rowspan="1" colspan="1">volume of distribution at steady state</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cmax</td><td align="left" valign="middle" rowspan="1" colspan="1">maximum plasma concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vc</td><td align="left" valign="middle" rowspan="1" colspan="1">volume of (distribution) central compartment</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00275"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marianecci</surname><given-names>C.</given-names></name>
<name><surname>Di Marzio</surname><given-names>L.</given-names></name>
<name><surname>Rinaldi</surname><given-names>F.</given-names></name>
<name><surname>Celia</surname><given-names>C.</given-names></name>
<name><surname>Paolino</surname><given-names>D.</given-names></name>
<name><surname>Alhaique</surname><given-names>F.</given-names></name>
<name><surname>Esposito</surname><given-names>S.</given-names></name>
<name><surname>Carafa</surname><given-names>M.</given-names></name>
</person-group><article-title>Niosomes from 80s to present: The state of the art</article-title><source>Adv. Colloid Interface Sci.</source><year>2014</year><volume>205</volume><fpage>187</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.cis.2013.11.018</pub-id><pub-id pub-id-type="pmid">24369107</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00275"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hancock</surname><given-names>R.E.W.</given-names></name>
<name><surname>Raffle</surname><given-names>V.J.</given-names></name>
<name><surname>Nicas</surname><given-names>T.I.</given-names></name>
</person-group><article-title>Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa</article-title><source>Antimicrob. Agents Chemother.</source><year>1981</year><volume>19</volume><fpage>777</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1128/AAC.19.5.777</pub-id><pub-id pub-id-type="pmid">6794444</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00275"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jankie</surname><given-names>S.</given-names></name>
<name><surname>Johnson</surname><given-names>J.</given-names></name>
<name><surname>Pinto Pereira</surname><given-names>L.M.</given-names></name>
<name><surname>Adebayo</surname><given-names>A.S.</given-names></name>
<name><surname>Pillai</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Acute and Subacute Toxicity of Sorbitan Monostearate (Span 60) Non-ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats</article-title><source>Br. J. Pharm. Res.</source><year>2016</year><volume>14</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.9734/BJPR/2016/29932</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-00275"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akbarzadeh</surname><given-names>I.</given-names></name>
<name><surname>Yaraki</surname><given-names>M.T.</given-names></name>
<name><surname>Bourbour</surname><given-names>M.</given-names></name>
<name><surname>Noorbazargan</surname><given-names>H.</given-names></name>
<name><surname>Lajevardi</surname><given-names>A.</given-names></name>
<name><surname>Shilsar</surname><given-names>S.M.S.</given-names></name>
<name><surname>Heidari</surname><given-names>F.</given-names></name>
<name><surname>Mousavian</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Optimized doxycycline-loaded niosomal formulation for treatment of infection-associated prostate cancer: An in-vitro investigation</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>57</volume><fpage>101715</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2020.101715</pub-id></element-citation></ref><ref id="B5-pharmaceutics-17-00275"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Estanqueiro</surname><given-names>M.</given-names></name>
<name><surname>Amaral</surname><given-names>M.H.</given-names></name>
<name><surname>Concei&#x000e7;&#x000e3;o</surname><given-names>J.</given-names></name>
<name><surname>Lobo</surname><given-names>J.M.S.</given-names></name>
</person-group><article-title>Nanotechnological carriers for cancer chemotherapy: The state of the art</article-title><source>Colloids Surf. B Biointerfaces</source><year>2015</year><volume>126</volume><fpage>631</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2014.12.041</pub-id><pub-id pub-id-type="pmid">25591851</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00275"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paganoni</surname><given-names>R.</given-names></name>
<name><surname>Herzog</surname><given-names>C.</given-names></name>
<name><surname>Braunsteiner</surname><given-names>A.</given-names></name>
<name><surname>Hohl</surname><given-names>P.</given-names></name>
</person-group><article-title>Fleroxacin: In-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin</article-title><source>J. Antimicrob. Chemother.</source><year>1988</year><volume>22</volume><issue>(Suppl. D)</issue><fpage>3</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1093/jac/22.Supplement_D.3</pub-id><pub-id pub-id-type="pmid">3144545</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00275"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Subramaniam</surname><given-names>S.</given-names></name>
<name><surname>Joyce</surname><given-names>P.</given-names></name>
<name><surname>Thomas</surname><given-names>N.</given-names></name>
<name><surname>Prestidge</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Bioinspired drug delivery strategies for repurposing conventional antibiotics against intracellular infections</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>177</volume><fpage>113948</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.113948</pub-id><pub-id pub-id-type="pmid">34464665</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00275"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fr&#x000f6;hlich</surname><given-names>E.</given-names></name>
</person-group><article-title>The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles</article-title><source>Int. J. Nanomed.</source><year>2012</year><volume>7</volume><fpage>5577</fpage><lpage>5591</lpage><pub-id pub-id-type="doi">10.2147/IJN.S36111</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-00275"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koeppe</surname><given-names>M.O.</given-names></name>
<name><surname>Cristofoletti</surname><given-names>R.</given-names></name>
<name><surname>Fernandes</surname><given-names>E.F.</given-names></name>
<name><surname>Storpirtis</surname><given-names>S.</given-names></name>
<name><surname>Junginger</surname><given-names>H.E.</given-names></name>
<name><surname>Kopp</surname><given-names>S.</given-names></name>
<name><surname>Midha</surname><given-names>K.K.</given-names></name>
<name><surname>Shah</surname><given-names>V.P.</given-names></name>
<name><surname>Stavchansky</surname><given-names>S.</given-names></name>
<name><surname>Dressman</surname><given-names>J.B.</given-names></name>
<etal/>
</person-group><article-title>Biowaiver monographs for immediate release solid oral dosage forms: Levofloxacin</article-title><source>J. Pharm. Sci.</source><year>2011</year><volume>100</volume><fpage>1628</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1002/jps.22413</pub-id><pub-id pub-id-type="pmid">21374601</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00275"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blokhina</surname><given-names>S.V.</given-names></name>
<name><surname>Sharapova</surname><given-names>A.V.</given-names></name>
<name><surname>Ol&#x02019;khovich</surname><given-names>M.V.</given-names></name>
<name><surname>Volkova</surname><given-names>T.V.</given-names></name>
<name><surname>Perlovich</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials</article-title><source>Eur. J. Pharm. Sci.</source><year>2016</year><volume>93</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2016.07.016</pub-id><pub-id pub-id-type="pmid">27473309</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00275"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fish</surname><given-names>D.N.</given-names></name>
<name><surname>Chow</surname><given-names>A.T.</given-names></name>
</person-group><article-title>The clinical pharmacokinetics of levofloxacin</article-title><source>Clin. Pharmacokinet.</source><year>1997</year><volume>32</volume><fpage>101</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.2165/00003088-199732020-00002</pub-id><pub-id pub-id-type="pmid">9068926</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00275"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Behroozi</surname><given-names>R.</given-names></name>
<name><surname>Dehghanian</surname><given-names>E.</given-names></name>
</person-group><article-title>Drug repurposing study of levofloxacin: Structural properties, lipophilicity along with experimental and computational DNA binding</article-title><source>J. Mol. Liq.</source><year>2024</year><volume>407</volume><fpage>125218</fpage><pub-id pub-id-type="doi">10.1016/j.molliq.2024.125218</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-00275"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikaido</surname><given-names>H.</given-names></name>
<name><surname>Vaara</surname><given-names>M.</given-names></name>
</person-group><article-title>Molecular basis of bacterial outer membrane permeability</article-title><source>Microbiol. Rev.</source><year>1985</year><volume>49</volume><fpage>1</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1128/mr.49.1.1-32.1985</pub-id><pub-id pub-id-type="pmid">2580220</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00275"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bedard</surname><given-names>J.</given-names></name>
<name><surname>Wong</surname><given-names>S.</given-names></name>
<name><surname>Bryan</surname><given-names>L.E.</given-names></name>
</person-group><article-title>Accumulation of enoxacin by Escherichia coli and Bacillus subtilis</article-title><source>Antimicrob. Agents Chemother.</source><year>1987</year><volume>31</volume><fpage>1348</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1128/AAC.31.9.1348</pub-id><pub-id pub-id-type="pmid">2823695</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00275"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bilardi</surname><given-names>C.</given-names></name>
<name><surname>Dulbecco</surname><given-names>P.</given-names></name>
<name><surname>Zentilin</surname><given-names>P.</given-names></name>
<name><surname>Reglioni</surname><given-names>S.</given-names></name>
<name><surname>Iiritano</surname><given-names>E.</given-names></name>
<name><surname>Parodi</surname><given-names>A.</given-names></name>
<name><surname>Accornero</surname><given-names>L.</given-names></name>
<name><surname>Savarino</surname><given-names>E.</given-names></name>
<name><surname>Mansi</surname><given-names>C.</given-names></name>
<name><surname>Mamone</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2004</year><volume>2</volume><fpage>997</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1016/S1542-3565(04)00458-6</pub-id><pub-id pub-id-type="pmid">15551252</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00275"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Lu</surname><given-names>B.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
</person-group><article-title>Helicobacter pylori and antibiotic resistance, a continuing and intractable problem</article-title><source>Helicobacter</source><year>2016</year><volume>21</volume><fpage>349</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1111/hel.12299</pub-id><pub-id pub-id-type="pmid">26822340</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00275"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>Y.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Naika</surname><given-names>Y.</given-names></name>
<name><surname>Maeda</surname><given-names>T.</given-names></name>
<name><surname>Otsuka</surname><given-names>Y.</given-names></name>
<name><surname>Saeki</surname><given-names>Y.</given-names></name>
<name><surname>Otani</surname><given-names>S.</given-names></name>
<name><surname>Kohama</surname><given-names>K.</given-names></name>
<name><surname>Hieda</surname><given-names>Y.</given-names></name>
<name><surname>Goromaru</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Ester Prodrugs of Levofloxacin to Prevent Chelate Formation in Presence of Aluminium Ion</article-title><source>Pharm. Sci.</source><year>2023</year><volume>29</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.34172/PS.2022.15</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-00275"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Islan</surname><given-names>G.A.</given-names></name>
<name><surname>Tornello</surname><given-names>P.C.</given-names></name>
<name><surname>Abraham</surname><given-names>G.A.</given-names></name>
<name><surname>Duran</surname><given-names>N.</given-names></name>
<name><surname>Castro</surname><given-names>G.R.</given-names></name>
</person-group><article-title>Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization</article-title><source>Colloids Surf. B Biointerfaces</source><year>2016</year><volume>143</volume><fpage>168</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2016.03.040</pub-id><pub-id pub-id-type="pmid">27003467</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00275"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cicuendez</surname><given-names>M.</given-names></name>
<name><surname>Izquierdo-Barba</surname><given-names>I.</given-names></name>
<name><surname>Portol&#x000e9;s</surname><given-names>M.T.</given-names></name>
<name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name>
</person-group><article-title>Biocompatibility and levofloxacin delivery of mesoporous materials</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2013</year><volume>84</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2012.11.029</pub-id><pub-id pub-id-type="pmid">23275112</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00275"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Konreddy</surname><given-names>A.K.</given-names></name>
<name><surname>Rani</surname><given-names>G.U.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Choi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Recent drug-repurposing-driven advances in the discovery of novel antibiotics</article-title><source>Curr. Med. Chem.</source><year>2019</year><volume>26</volume><fpage>5363</fpage><lpage>5388</lpage><pub-id pub-id-type="doi">10.2174/0929867325666180706101404</pub-id><pub-id pub-id-type="pmid">29984648</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00275"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derbali</surname><given-names>R.M.</given-names></name>
<name><surname>Aoun</surname><given-names>V.</given-names></name>
<name><surname>Moussa</surname><given-names>G.</given-names></name>
<name><surname>Frei</surname><given-names>G.</given-names></name>
<name><surname>Tehrani</surname><given-names>S.F.</given-names></name>
<name><surname>Del&#x02019;Orto</surname><given-names>J.C.</given-names></name>
<name><surname>Hildgen</surname><given-names>P.</given-names></name>
<name><surname>Roullin</surname><given-names>V.G.</given-names></name>
<name><surname>Chain</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: A comparative study</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>1906</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b01256</pub-id><pub-id pub-id-type="pmid">30900903</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00275"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jankie</surname><given-names>S.</given-names></name>
<name><surname>Adebayo</surname><given-names>A.S.</given-names></name>
<name><surname>Pillai</surname><given-names>G.</given-names></name>
</person-group><article-title>In vitro activities of fluoroquinolones entrapped in non-ionic surfactant vesicles against ciprofloxacin-resistant bacteria strains</article-title><source>J. Pharm. Technol. Drug Res.</source><year>2012</year><volume>1</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="B23-pharmaceutics-17-00275"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uchegbu</surname><given-names>I.F.</given-names></name>
<name><surname>Florence</surname><given-names>A.T.</given-names></name>
</person-group><article-title>Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry</article-title><source>Adv. Colloid Interface Sci.</source><year>1995</year><volume>58</volume><fpage>1</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/0001-8686(95)00242-I</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-00275"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>S.M.</given-names></name>
<name><surname>Rosskopf</surname><given-names>E.N.</given-names></name>
<name><surname>Leesch</surname><given-names>J.G.</given-names></name>
<name><surname>Chellemi</surname><given-names>D.O.</given-names></name>
<name><surname>Bull</surname><given-names>C.T.</given-names></name>
<name><surname>Mazzola</surname><given-names>M.</given-names></name>
</person-group><article-title>United States Department of Agriculture&#x02014;Agricultural Research Service research on alternatives to methyl bromide: Pre-plant and post-harvest</article-title><source>Pest. Manag. Sci. Former. Pestic. Sci.</source><year>2003</year><volume>59</volume><fpage>814</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1002/ps.728</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-00275"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>National Institutes of Health (US)</collab>
</person-group><source>Animal Research Committee, &#x00026; NIH Office of Animal Care. Using Animals in Intramural Research: Guidelines for Investigators and Guidelines for Animal Users</source><publisher-name>NIH Animal Research Advisory Committee</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>1999</year></element-citation></ref><ref id="B26-pharmaceutics-17-00275"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wadham</surname><given-names>J.J.B.</given-names></name>
<name><surname>Townsend</surname><given-names>P.</given-names></name>
<name><surname>Morton</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Intraperitoneal injection of sodium pentobarbital as a method for euthanasia for rodents</article-title><source>Aust. N. Zeal. Counc. Care Anim. Res. Teach.</source><year>1997</year><volume>10</volume><fpage>8</fpage></element-citation></ref><ref id="B27-pharmaceutics-17-00275"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooke</surname><given-names>R.</given-names></name>
<name><surname>Jeeves</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Direct Search&#x0201d; Solution of Numerical and Statistical Problems</article-title><source>J. ACM (JACM)</source><year>1961</year><volume>8</volume><fpage>212</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1145/321062.321069</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-00275"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Siefert</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Model-Assisted Pattern Search</article-title><source>Doctoral Dissertation</source><publisher-name>College of William and Mary</publisher-name><year>2000</year></element-citation></ref><ref id="B29-pharmaceutics-17-00275"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akaike</surname><given-names>H.</given-names></name>
</person-group><article-title>A new look at the statistical model identification</article-title><source>IEEE Trans. Autom. Control</source><year>1974</year><volume>19</volume><fpage>716</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1109/TAC.1974.1100705</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-00275"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sugiura</surname><given-names>N.</given-names></name>
</person-group><article-title>Further analysis of the data by akaike&#x02019;s information criterion and the finite corrections: Further analysis of the data by akaike&#x02019;s</article-title><source>Commun. Stat.-Theory Methods</source><year>1978</year><volume>7</volume><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1080/03610927808827599</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-00275"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwarz</surname><given-names>G.</given-names></name>
</person-group><article-title>Estimating the dimension of a model</article-title><source>Ann. Stat.</source><year>1978</year><volume>6</volume><fpage>461</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1214/aos/1176344136</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-00275"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danaei</surname><given-names>M.</given-names></name>
<name><surname>Dehghankhold</surname><given-names>M.</given-names></name>
<name><surname>Ataei</surname><given-names>S.</given-names></name>
<name><surname>Hasanzadeh Davarani</surname><given-names>F.</given-names></name>
<name><surname>Javanmard</surname><given-names>R.</given-names></name>
<name><surname>Dokhani</surname><given-names>A.</given-names></name>
<name><surname>Khorasani</surname><given-names>S.</given-names></name>
<name><surname>Mozafari</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics10020057</pub-id><pub-id pub-id-type="pmid">29783687</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00275"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Deng</surname><given-names>C.</given-names></name>
<name><surname>Fu</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Gong</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response</article-title><source>Mol. Pharm.</source><year>2016</year><volume>13</volume><fpage>1800</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00952</pub-id><pub-id pub-id-type="pmid">27112287</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00275"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurtado</surname><given-names>F.K.</given-names></name>
<name><surname>Weber</surname><given-names>B.</given-names></name>
<name><surname>Derendorf</surname><given-names>H.</given-names></name>
<name><surname>Hochhaus</surname><given-names>G.</given-names></name>
<name><surname>Dalla Costa</surname><given-names>T.</given-names></name>
</person-group><article-title>Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>678</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1128/AAC.01884-13</pub-id><pub-id pub-id-type="pmid">24217697</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00275"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nix</surname><given-names>D.E.</given-names></name>
<name><surname>Goodwin</surname><given-names>S.D.</given-names></name>
<name><surname>Peloquin</surname><given-names>C.A.</given-names></name>
<name><surname>Rotella</surname><given-names>D.L.</given-names></name>
<name><surname>Schentag</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning</article-title><source>Antimicrob. Agents Chemother.</source><year>1991</year><volume>35</volume><fpage>1947</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1128/AAC.35.10.1947</pub-id><pub-id pub-id-type="pmid">1759812</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00275"><label>36.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Dalhoff</surname><given-names>A.</given-names></name>
</person-group><article-title>A review of quinolone pharmacokinetics</article-title><source>Tele-Symposium on Quinolones</source><person-group person-group-type="editor">
<name><surname>Fernandes</surname><given-names>P.B.</given-names></name>
</person-group><publisher-name>JR Prous Science Publishers</publisher-name><publisher-loc>Barcelona, Spain</publisher-loc><year>1989</year><fpage>277</fpage><lpage>312</lpage></element-citation></ref><ref id="B37-pharmaceutics-17-00275"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Easmon</surname><given-names>C.S.</given-names></name>
<name><surname>Crane</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Uptake of ciprofloxacin by human neutrophils</article-title><source>J. Antimicrob. Chemother.</source><year>1985</year><volume>16</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/jac/16.1.67</pub-id><pub-id pub-id-type="pmid">2931414</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00275"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruckmani</surname><given-names>K.</given-names></name>
<name><surname>Sankar</surname><given-names>V.</given-names></name>
<name><surname>Sivakumar</surname><given-names>M.</given-names></name>
</person-group><article-title>Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes</article-title><source>J. Biomed. Nanotechnol.</source><year>2010</year><volume>6</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1166/jbn.2010.1101</pub-id><pub-id pub-id-type="pmid">20499831</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00275"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ammar</surname><given-names>H.O.</given-names></name>
<name><surname>Haider</surname><given-names>M.</given-names></name>
<name><surname>Ibrahim</surname><given-names>M.</given-names></name>
<name><surname>El Hoffy</surname><given-names>N.M.</given-names></name>
</person-group><article-title>In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration</article-title><source>Drug Deliv.</source><year>2017</year><volume>24</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1080/10717544.2016.1259371</pub-id><pub-id pub-id-type="pmid">28165822</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00275"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feitosa</surname><given-names>R.C.</given-names></name>
<name><surname>Ishikawa</surname><given-names>E.S.</given-names></name>
<name><surname>da Silva</surname><given-names>M.F.</given-names></name>
<name><surname>da Silva-Junior</surname><given-names>A.A.</given-names></name>
<name><surname>Oliveira-Nascimento</surname><given-names>L.</given-names></name>
</person-group><article-title>Five decades of doxycycline: Does nanotechnology improve its properties?</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>618</volume><fpage>121655</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.121655</pub-id><pub-id pub-id-type="pmid">35283220</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00275"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nestorov</surname><given-names>I.A.</given-names></name>
<name><surname>Aarons</surname><given-names>L.J.</given-names></name>
<name><surname>Arundel</surname><given-names>P.A.</given-names></name>
<name><surname>Rowland</surname><given-names>M.</given-names></name>
</person-group><article-title>Lumping of whole-body physiologically based pharmacokinetic models</article-title><source>J. Pharmacokinet. Biopharm.</source><year>1998</year><volume>26</volume><fpage>21</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1023/A:1023272707390</pub-id><pub-id pub-id-type="pmid">9773391</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00275"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeong</surname><given-names>Y.S.</given-names></name>
<name><surname>Kim</surname><given-names>M.S.</given-names></name>
<name><surname>Chung</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Determination of the number of tissue groups of kinetically distinct transit time in whole-body physiologically based pharmacokinetic (PBPK) models I: Theoretical consideration of bottom-up approach of lumping tissues in whole-body PBPK</article-title><source>AAPS J.</source><year>2022</year><volume>24</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1208/s12248-022-00732-y</pub-id><pub-id pub-id-type="pmid">36002760</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00275"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="editor">
<name><surname>Burnham</surname><given-names>K.P.</given-names></name>
<name><surname>Anderson</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach</article-title><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2002</year></element-citation></ref><ref id="B44-pharmaceutics-17-00275"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Q.</given-names></name>
<name><surname>Deng</surname><given-names>W.</given-names></name>
<name><surname>Yuan</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group><article-title>Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>122</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.10.010</pub-id><pub-id pub-id-type="pmid">29032193</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00275"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bayindir</surname><given-names>Z.S.</given-names></name>
<name><surname>Be&#x0015f;ikci</surname><given-names>A.</given-names></name>
<name><surname>Y&#x000fc;ksel</surname><given-names>N.</given-names></name>
</person-group><article-title>Paclitaxel-loaded niosomes for intravenous administration: Pharmacokinetics and tissue distribution in rats</article-title><source>Turk. J. Med. Sci.</source><year>2015</year><volume>45</volume><fpage>1403</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.3906/sag-1408-129</pub-id><pub-id pub-id-type="pmid">26775401</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00275-f001"><label>Figure 1</label><caption><p>(<bold>A</bold>) Scanning electron microscope of levofloxacin niosomes. (<bold>B</bold>) Transmission electron microscopy of levofloxacin niosomes.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>) Typical niosome size distribution. (<bold>B</bold>) Typical niosome Zeta potential plot.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g002a" position="float"/><graphic xlink:href="pharmaceutics-17-00275-g002b" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f003"><label>Figure 3</label><caption><p>(<bold>A</bold>) Response surface for the interaction between input variables and their impact on (<bold>A</bold>) niosome drug encapsulation. (<bold>B</bold>) Response surface for the interaction between input variables and their impact on vesicle (niosome) size. (<bold>C</bold>) Response surface for the interaction between input variables and their impact on polydispersity index (PDI). Legend represents vesicle size, EE or PDI respectively.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g003a" position="float"/><graphic xlink:href="pharmaceutics-17-00275-g003b" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f004"><label>Figure 4</label><caption><p>(<bold>A</bold>) Typical chromatogram of levofloxacin on reverse phase HPLC column (ACN:H<sub>2</sub>O, +0.75%TFA gradient mode). (<bold>B</bold>) Reverse phase HPLC calibration curve for levofloxacin in the method (ACN:H<sub>2</sub>O; 60:40). Legend represents vesicle size, EE or PDI respectively.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g004a" position="float"/><graphic xlink:href="pharmaceutics-17-00275-g004b" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f005"><label>Figure 5</label><caption><p>Intra-day and inter-day stability of levofloxacin concentrations during HPLC analysis.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f006"><label>Figure 6</label><caption><p>Dissolution profiles of levofloxacin-loaded niosomes from screening (red) and optimized (blue) formulations.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g006" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f007"><label>Figure 7</label><caption><p>(<bold>A</bold>) Cp vs. t for levofloxacin niosomes. Each colored box represents a Cp vs. time profile of an animal; lines represent lines of best fit. (<bold>B</bold>) log Cp vs. t for levofloxacin niosomes. Each colored box represents a Cp vs. time profile of an animal; lines represent lines of best fit. (<bold>C</bold>) Plot of residuals for levofloxacin niosomes. Each colored box represents residuals for a Cp vs. time profile of an animal; lines represent lines of best fit.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g007" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f008"><label>Figure 8</label><caption><p>(<bold>A</bold>) Cp vs. t for pure unencapsulated levofloxacin. Each colored box represents a Cp vs. time profile of an animal; lines represent lines of best fit. (<bold>B</bold>) log Cp vs. t for pure unencapsulated levofloxacin. Each colored box represents a Cp vs. time profile of an animal; lines represent lines of best fit. (<bold>C</bold>) Plot of residuals for pure, unencapsulated levofloxacin. Each colored box represents residuals for a Cp vs. time profile of an animal; lines represent lines of best fit.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g008" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f009"><label>Figure 9</label><caption><p>Average Cp vs. times for rats administered levofloxacin niosomes and those with pure levofloxacin.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g009" position="float"/></fig><fig position="float" id="pharmaceutics-17-00275-f010"><label>Figure 10</label><caption><p>Mean residence time (MRT) of niosomes vs. pure drug levofloxacin.</p></caption><graphic xlink:href="pharmaceutics-17-00275-g010" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00275-t001"><object-id pub-id-type="pii">pharmaceutics-17-00275-t001_Table 1</object-id><label>Table 1</label><caption><p>Excipient molar ratio (input variables) and response variables from screening experiments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Run No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CHOL (mM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SP60 (mM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DCP (mM%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EE (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PDI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">* Vesicle Size (nm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Zeta (mV)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">24.921</td><td align="center" valign="middle" rowspan="1" colspan="1">0.216</td><td align="center" valign="middle" rowspan="1" colspan="1">203.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">29.059</td><td align="center" valign="middle" rowspan="1" colspan="1">0.230</td><td align="center" valign="middle" rowspan="1" colspan="1">238.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;50.83</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">30.118</td><td align="center" valign="middle" rowspan="1" colspan="1">0.234</td><td align="center" valign="middle" rowspan="1" colspan="1">249.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.35</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">22.230</td><td align="center" valign="middle" rowspan="1" colspan="1">0.239</td><td align="center" valign="middle" rowspan="1" colspan="1">212.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">20.841</td><td align="center" valign="middle" rowspan="1" colspan="1">0.237</td><td align="center" valign="middle" rowspan="1" colspan="1">261.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;79.67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">9.549</td><td align="center" valign="middle" rowspan="1" colspan="1">0.234</td><td align="center" valign="middle" rowspan="1" colspan="1">204.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">22.8169</td><td align="center" valign="middle" rowspan="1" colspan="1">0.271</td><td align="center" valign="middle" rowspan="1" colspan="1">355.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">8.051</td><td align="center" valign="middle" rowspan="1" colspan="1">0.281</td><td align="center" valign="middle" rowspan="1" colspan="1">248.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;48.71</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">3.75</td><td align="center" valign="middle" rowspan="1" colspan="1">10.229</td><td align="center" valign="middle" rowspan="1" colspan="1">0.247</td><td align="center" valign="middle" rowspan="1" colspan="1">265.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;42.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">10.482</td><td align="center" valign="middle" rowspan="1" colspan="1">0.380</td><td align="center" valign="middle" rowspan="1" colspan="1">783.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;125.45</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">34.213</td><td align="center" valign="middle" rowspan="1" colspan="1">0.316</td><td align="center" valign="middle" rowspan="1" colspan="1">368.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;147.36</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.39788</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.392</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">579</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;125.45</td></tr></tbody></table><table-wrap-foot><fn><p>CHOL = cholesterol; SP60 = Span 60 (surfactant, SAA); DCP = dihexadecyl phosphate; EE (%) = encapsulation efficiency; PDI = polydispersity index. * Vesicle size (nm) is the hydrodynamic diameter.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t002"><object-id pub-id-type="pii">pharmaceutics-17-00275-t002_Table 2</object-id><label>Table 2</label><caption><p>Regression ANOVA statistics for vesicle size.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source of Variation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sum of Squares</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Degrees of Freedom</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean Square</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">F-Ratio</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Regression</td><td align="center" valign="middle" rowspan="1" colspan="1">102,883.119</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">102,883.119</td><td align="center" valign="middle" rowspan="1" colspan="1">4.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Residual</td><td align="center" valign="middle" rowspan="1" colspan="1">242,484.078</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">24,248.408</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.903</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lack-Of-Fit</td><td align="center" valign="middle" rowspan="1" colspan="1">17,860.654</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5953.551</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pure Error</td><td align="center" valign="middle" rowspan="1" colspan="1">224,623.424</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">32,089.061</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">345,367.197</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t003"><object-id pub-id-type="pii">pharmaceutics-17-00275-t003_Table 3</object-id><label>Table 3</label><caption><p>Model term ranking for encapsulation efficiency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Term Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Term Range</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coefficient Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Term Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Term Rank</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">X2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.000</td><td align="center" valign="middle" rowspan="1" colspan="1">11.757</td><td align="center" valign="middle" rowspan="1" colspan="1">23.513</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(X1)<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1">21.970</td><td align="center" valign="middle" rowspan="1" colspan="1">21.970</td><td align="center" valign="middle" rowspan="1" colspan="1">0.934</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X1 &#x000d7; X2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;9.915</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;19.829</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.843</td></tr></tbody></table><table-wrap-foot><fn><p>X1 = CHOL; X2 = SP60.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t004"><object-id pub-id-type="pii">pharmaceutics-17-00275-t004_Table 4</object-id><label>Table 4</label><caption><p>Independent variable setting and predicted response data from the DoE Optimizer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Response Variable Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relative Importance</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Optimizer Answer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2 Sigma</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">+2 Sigma</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Predicted Response</td><td align="center" valign="middle" rowspan="1" colspan="1">Confidence Limit</td><td align="center" valign="middle" rowspan="1" colspan="1">Confidence Limit</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EE (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Maximize</td><td align="center" valign="middle" rowspan="1" colspan="1">30.738</td><td align="center" valign="middle" rowspan="1" colspan="1">13.381</td><td align="center" valign="middle" rowspan="1" colspan="1">48.095</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PDI</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Maximize</td><td align="center" valign="middle" rowspan="1" colspan="1">0.286</td><td align="center" valign="middle" rowspan="1" colspan="1">0.245</td><td align="center" valign="middle" rowspan="1" colspan="1">0.328</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vesicle Size (nm)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Minimize</td><td align="center" valign="middle" rowspan="1" colspan="1">329.160</td><td align="center" valign="middle" rowspan="1" colspan="1">41.103</td><td align="center" valign="middle" rowspan="1" colspan="1">617.217</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zeta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximize</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;51.609</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;124.639</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.421</td></tr></tbody></table><table-wrap-foot><fn><p>Predicted response data: desirability target = 1.0; desirability result = 0.6.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t005"><object-id pub-id-type="pii">pharmaceutics-17-00275-t005_Table 5</object-id><label>Table 5</label><caption><p>HPLC analytical parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Analytical Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">USP Limits</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Linearity</td><td align="center" valign="middle" rowspan="1" colspan="1">y = 294.06x; R&#x000b2; = 0.999</td><td align="center" valign="middle" rowspan="1" colspan="1">R&#x000b2; = 0.980</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mean RT (min)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.090 (&#x000b1;0.05) min</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">99.66% (&#x000b1;3.36)</td><td align="center" valign="middle" rowspan="1" colspan="1">85&#x02013;115%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LOD &#x003bc;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">10.00 </td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LOQ (&#x003bc;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.25 </td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean Recovery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.90% (&#x000b1; 1.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85&#x02013;115%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t006"><object-id pub-id-type="pii">pharmaceutics-17-00275-t006_Table 6</object-id><label>Table 6</label><caption><p>A measure of precision and accuracy in the determination of levofloxacin concentration in rat serum. (n =18).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Concentration &#x000b5;g/mL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RE (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intra-Day Variation (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inter-Day Variation (%)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.025 &#x000b1; 0.083</td><td align="center" valign="middle" rowspan="1" colspan="1">1.242</td><td align="center" valign="middle" rowspan="1" colspan="1">6.116</td><td align="center" valign="middle" rowspan="1" colspan="1">4.451</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.100 &#x000b1; 0.091</td><td align="center" valign="middle" rowspan="1" colspan="1">2.503</td><td align="center" valign="middle" rowspan="1" colspan="1">2.341</td><td align="center" valign="middle" rowspan="1" colspan="1">4.419</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">6.041 &#x000b1; 0.123</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">2.837</td><td align="center" valign="middle" rowspan="1" colspan="1">1.585</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.023 &#x000b1; 0.135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.288</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.724</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.346</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t007"><object-id pub-id-type="pii">pharmaceutics-17-00275-t007_Table 7</object-id><label>Table 7</label><caption><p>Non-compartment open model for levofloxacin in Sprague Dawley rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Niosomes</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pure Levofloxacin</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Units</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STD</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>(0-inf)</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g-h/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">2.78 &#x000d7; 10<sup>4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">12,647.160</td><td align="center" valign="middle" rowspan="1" colspan="1">6.89 &#x000d7; 10<sup>3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4236.170</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AUMC</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g-h<sup>2</sup>/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">5.75 &#x000d7; 10<sup>5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">309,275.070</td><td align="center" valign="middle" rowspan="1" colspan="1">9.63 &#x000d7; 10<sup>4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">124,749.700</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRT</td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">20.7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.410</td><td align="center" valign="middle" rowspan="1" colspan="1">13.980</td><td align="center" valign="middle" rowspan="1" colspan="1">8.310</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h</td><td align="center" valign="middle" rowspan="1" colspan="1">7.12 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>(z)</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">4.02 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">5 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>ss</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.39 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>(0)</sub> bolus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.64 &#x000d7; 10<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">763.850</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">626.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">416.460</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t008"><object-id pub-id-type="pii">pharmaceutics-17-00275-t008_Table 8</object-id><label>Table 8</label><caption><p>One-compartment open model for levofloxacin in Sprague Dawley rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PK Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Niosomes</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pure Levofloxacin</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pure Levofloxacin</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Units</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Values</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Values</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vd</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.64 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">43.96%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.20 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.86%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">1.81 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">19.16%</td><td align="center" valign="middle" rowspan="1" colspan="1">3.95 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.53%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vd/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">7.37 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">43.96%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.75 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.86%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K10 </td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">47.95%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL/mg Dose</td><td align="center" valign="middle" rowspan="1" colspan="1">665.1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">453.9</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">t<sub>1/2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">28.16</td><td align="center" valign="middle" rowspan="1" colspan="1">47.95%</td><td align="center" valign="middle" rowspan="1" colspan="1">17.09</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AUC</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g-h/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">3.91 &#x000d7; 10<sup>4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">51.64%</td><td align="center" valign="middle" rowspan="1" colspan="1">7327.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AUMC</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g-h<sup>2</sup>/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">1.70 &#x000d7; 10<sup>6</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">51.64%</td><td align="center" valign="middle" rowspan="1" colspan="1">4.55 &#x000d7; 10<sup>5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.14%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRT</td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">40.62</td><td align="center" valign="middle" rowspan="1" colspan="1">47.95%</td><td align="center" valign="middle" rowspan="1" colspan="1">24.66</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.418</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.335</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Model parameters: Akaike information criterion (AIC) = (#Pts) &#x000d7; Log(Obj) + 2(#Parameters) = &#x02212;11.3715; Schwarz criterion (SC) = (#Pts) &#x000d7; Log(Obj) + (#Parameters) &#x000d7; (Log(#Pts)) = &#x02212;7.1828; optimization time: 7.422 &#x000d7; 10<sup>&#x02212;2</sup> s; total simulations: 594; weighted sum of squared errors = 7.740 &#x000d7; 10<sup>&#x02212;1</sup>; weighting: 1/Yhat<sup>2</sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t009"><object-id pub-id-type="pii">pharmaceutics-17-00275-t009_Table 9</object-id><label>Table 9</label><caption><p>Two-compartment open model for levofloxacin and its niosome in Sprague Dawley rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PK Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Niosomes</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pure Levofloxacin</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pure Levofloxacin</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Units</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Values</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Values</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vc </td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.63 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">53.16%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">81.69%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L/h</td><td align="center" valign="middle" rowspan="1" colspan="1">1.62 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6289.32%</td><td align="center" valign="middle" rowspan="1" colspan="1">3.08 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">39.17%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00%</td><td align="center" valign="middle" rowspan="1" colspan="1">4.52 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6.64%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3918.40%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.55<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7.55%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vc/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">7.36 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">53.16%</td><td align="center" valign="middle" rowspan="1" colspan="1">6.52 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">81.69%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL<sub>2</sub>/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">7.28 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6289.32%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">39.17%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>2</sub>/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">0.152</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.020</td><td align="center" valign="middle" rowspan="1" colspan="1">6.64%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">1024.1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">897.400</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">8.066</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">222.700</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alpha </td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.308</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Beta </td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">2.85 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">8.66 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>10</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" rowspan="1" colspan="1">3918.76%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">82.04%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>12</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">9.89 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6289.55%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.209</td><td align="center" valign="middle" rowspan="1" colspan="1">90.59%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>21</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">4.78 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6289.32%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.068</td><td align="center" valign="middle" rowspan="1" colspan="1">39.73%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">665.6</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">678.9</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">t<sub>1/2</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">2431.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00%</td><td align="center" valign="middle" rowspan="1" colspan="1">80.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4183</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5749</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Model parameters: Akaike information criterion (AIC) = (#Pts) &#x000d7; Log(Obj) + 2(#Parameters) = &#x02212;7.369; Schwarz criterion (SC) = (#Pts) &#x000d7; Log(Obj) + (#Parameters) &#x000d7; (Log(#Pts)) = 1.009; optimization time: 0.363 s; total simulations: 2640; weighted sum of squared errors = 7.740 &#x000d7; 10<sup>&#x02212;1</sup>; weighting: 1/Yhat<sup>2</sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00275-t010"><object-id pub-id-type="pii">pharmaceutics-17-00275-t010_Table 10</object-id><label>Table 10</label><caption><p>Three-compartment open model for levofloxacin and its niosome in Sprague Dawley rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">PK Parameters</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Niosomes</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pure Levofloxacin</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Units</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Values</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Values</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h</td><td align="center" valign="middle" rowspan="1" colspan="1">3.50 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1407.07%</td><td align="center" valign="middle" rowspan="1" colspan="1">5.05 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">445.91%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vc </td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1467.27%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">114.24%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL<sub>2</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h</td><td align="center" valign="middle" rowspan="1" colspan="1">2.34 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2309.27%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.36 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3499.48%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">9.07 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">24,905.54%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.91 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5199.34%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L/h</td><td align="center" valign="middle" rowspan="1" colspan="1">5.43 &#x000d7; 10<sup>&#x02212;6</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10,224.64%</td><td align="center" valign="middle" rowspan="1" colspan="1">8.30 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10,381.48%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">6.03 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">557.66%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.22 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5648.0%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL/kg </td><td align="center" valign="middle" rowspan="1" colspan="1">L/h/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">1.58 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1407.07%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.24 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">445.91%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vc/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">6.96 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1467.27%</td><td align="center" valign="middle" rowspan="1" colspan="1">6.49 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">114.24%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL2/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td><td align="center" valign="middle" rowspan="1" colspan="1">2309.27%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3499.48%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V2/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">4.09 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">24,905.54%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td><td align="center" valign="middle" rowspan="1" colspan="1">5199.34%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL3/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">2.44 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10,224.64%</td><td align="center" valign="middle" rowspan="1" colspan="1">3.67 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10,381.48%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">L/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">0.027</td><td align="center" valign="middle" rowspan="1" colspan="1">557.66%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.80 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5648.00%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">A </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">60.72</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">888.9</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">1026.6</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">36.07</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">5.348</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">199.7</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>&#x003b1;</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">27.31</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.315</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>&#x003b2;</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>&#x003b3;</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">7.75 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">6.86 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>10</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">2032.92%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">460.31%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>12</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">1.515</td><td align="center" valign="middle" rowspan="1" colspan="1">2735.99%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.161</td><td align="center" valign="middle" rowspan="1" colspan="1">3501.35%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>21</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">25.79</td><td align="center" valign="middle" rowspan="1" colspan="1">25,012.37%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.081</td><td align="center" valign="middle" rowspan="1" colspan="1">6267.34%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>13</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">3.51 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10,329.38%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.057</td><td align="center" valign="middle" rowspan="1" colspan="1">10,382.11%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>31</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">1/h</td><td align="center" valign="middle" rowspan="1" colspan="1">8.99 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10,239.84%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">11,818.42%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL/mg Dose</td><td align="center" valign="middle" rowspan="1" colspan="1">704.4</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">681.6</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>0</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">1092.6</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">1124.7</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">t<sub>1/2</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">894.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0%</td><td align="center" valign="middle" rowspan="1" colspan="1">101</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.418</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5752</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Model parameters: Akaike information criterion (AIC) = (#Pts) &#x000d7; Log(Obj) + 2(#Parameters) = &#x02212;3.3697; Schwarz criterion (SC) = (#Pts) &#x000d7; Log(Obj) + (#Parameters) &#x000d7; (Log(#Pts)) = 9.1963; optimization time: 2.292969 s; total simulations: 3288; weighted sum of squared errors = 7.7402<sup>&#x02212;1</sup>; weighting: 1/Yhat<sup>2</sup>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>